| scholarly article | Q13442814 |
| P50 | author | Terence Y Pang | Q52315837 |
| Anthony J Hannan | Q56948753 | ||
| Xin Du | Q59553062 | ||
| P2093 | author name string | Xin Du | |
| Anthony J Hannan | |||
| Terence Y C Pang | |||
| P2860 | cites work | Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication | Q22253034 |
| Psychopathology in Verified Huntington's Disease Gene Carriers | Q22306267 | ||
| Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion | Q24310393 | ||
| Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls | Q48912841 | ||
| Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. | Q51997371 | ||
| Effects of stress on neurotrophic factor expression in the rat brain. | Q52011649 | ||
| Neuronal plasticity and survival in mood disorders. | Q52541461 | ||
| Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. | Q54624737 | ||
| Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. | Q55054754 | ||
| Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder | Q59791691 | ||
| 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? | Q67825075 | ||
| Modulation of 5HT1A responsiveness in CA1 pyramidal neurons by in vivo activation of corticosteroid receptors | Q71538680 | ||
| Depression type and depression severity in relation to risk of violent suicide attempt | Q72751708 | ||
| Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression. Relation to antidepressant response to amitriptyline and lithium + L-tryptophan | Q72779735 | ||
| The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture | Q73315942 | ||
| Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication | Q74424004 | ||
| Excess mortality of mental disorder | Q77670488 | ||
| Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study | Q80246032 | ||
| Early adversity and serotonin transporter genotype interact with hippocampal glucocorticoid receptor mRNA expression, corticosterone, and behavior in adult male rats | Q83777465 | ||
| Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity | Q95721056 | ||
| Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons | Q24317574 | ||
| Cortisol responses to emotional stress in men: association with a functional polymorphism in the 5HTR2C gene | Q24618453 | ||
| Increased anxiety of mice lacking the serotonin1A receptor | Q24655613 | ||
| Serotonin-1A receptor imaging in recurrent depression: replication and literature review | Q24657080 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity | Q28116228 | ||
| PET imaging of serotonin 1A receptor binding in depression | Q28138956 | ||
| Adult brain neurogenesis and psychiatry: a novel theory of depression | Q28140495 | ||
| Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 | ||
| Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression | Q28272707 | ||
| Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases | Q28334138 | ||
| Hippocampal damage associated with prolonged glucocorticoid exposure in primates | Q28335993 | ||
| Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules | Q28590634 | ||
| Serotonin receptor 1A knockout: an animal model of anxiety-related disorder | Q28592514 | ||
| Essential role of brain-derived neurotrophic factor in adult hippocampal function | Q28593001 | ||
| A neurotrophic model for stress-related mood disorders | Q29616291 | ||
| Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells | Q30779186 | ||
| Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. | Q30864695 | ||
| Short-term effects of olanzapine in Huntington disease. | Q32107515 | ||
| Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease | Q33239883 | ||
| Escitalopram reduces increased hippocampal cytogenesis in a genetic rat depression model | Q33327860 | ||
| Beyond the brain: widespread pathology in Huntington's disease | Q33483188 | ||
| Neurotrophins and depression | Q33547892 | ||
| Regulation of hippocampal progenitor cell survival, proliferation and dendritic development by BDNF. | Q33590090 | ||
| Neurotrophins and synaptic plasticity | Q33593433 | ||
| Familial psychiatric presentation of Huntington's disease | Q33683204 | ||
| Huntington's disease: from molecular pathogenesis to clinical treatment | Q33773061 | ||
| Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus | Q33954181 | ||
| Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain | Q33954187 | ||
| Exercise: a behavioral intervention to enhance brain health and plasticity | Q33959877 | ||
| Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression | Q33961770 | ||
| Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. | Q33976362 | ||
| Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy. | Q34008064 | ||
| A BDNF autocrine loop in adult sensory neurons prevents cell death. | Q34058587 | ||
| Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb | Q34067026 | ||
| 5-HT-HPA interactions in two models of transgenic mice relevant to major depression | Q34074197 | ||
| SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein | Q34083719 | ||
| Juvenile onset Huntington's disease--clinical and research perspectives. | Q34091006 | ||
| Neurotrophins and activity-dependent plasticity | Q34098269 | ||
| Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice | Q34135360 | ||
| Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease | Q34152284 | ||
| Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants | Q34211475 | ||
| Role of neurotrophic factors in the etiology and treatment of mood disorders | Q34303344 | ||
| Long-term outcome of presymptomatic testing in Huntington disease | Q34325599 | ||
| Neurotrophins and neuronal differentiation in the central nervous system. | Q34350923 | ||
| Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder | Q34374580 | ||
| Glial cell abnormalities in major psychiatric disorders: the evidence and implications | Q34384584 | ||
| Depresssion--emerging insights from neurobiology | Q34446950 | ||
| Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions | Q34456676 | ||
| The influence of gender on phenotype and disease progression in patients with Huntington's disease | Q34458645 | ||
| Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena | Q34484850 | ||
| Pathophysiology of depression: the concept of synaptic plasticity | Q34548351 | ||
| Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. | Q34551701 | ||
| Is it time to reassess the BDNF hypothesis of depression? | Q34663655 | ||
| Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration | Q34706597 | ||
| The HPA axis in major depression: classical theories and new developments | Q34803590 | ||
| Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone | Q34806426 | ||
| Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography | Q34828339 | ||
| Cell pathology in mood disorders | Q34968512 | ||
| Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration | Q35054916 | ||
| Psychological autopsy studies of suicide: a systematic review | Q35109958 | ||
| Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression | Q35111592 | ||
| Neuropsychiatric aspects of Huntington's disease. | Q35463916 | ||
| Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment | Q35562268 | ||
| Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. | Q36024880 | ||
| Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease | Q36136010 | ||
| Stress models of depression: forming genetically vulnerable strains | Q36145101 | ||
| Mutant mouse models of depression: candidate genes and current mouse lines | Q36145108 | ||
| Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications | Q36205374 | ||
| Psychiatric disorders in preclinical Huntington's disease | Q36227490 | ||
| Glial reduction in the subgenual prefrontal cortex in mood disorders | Q36651128 | ||
| Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study | Q36696405 | ||
| Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice | Q36759748 | ||
| Obsessive and compulsive symptoms in prediagnosed Huntington's disease | Q36856810 | ||
| Biochemical aspects of Huntington's chorea | Q37053519 | ||
| Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter | Q37062125 | ||
| Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus | Q37118396 | ||
| Patterns of serotonergic antidepressant usage in prodromal Huntington disease | Q37148863 | ||
| Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates | Q37216621 | ||
| Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease | Q37250423 | ||
| Regulation of the hypothalamic-pituitary-adrenal axis | Q37538330 | ||
| Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. | Q37595989 | ||
| Omega-3 fatty acids in major depressive disorder | Q37631816 | ||
| Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity | Q37661598 | ||
| Early life influences on emotional reactivity: evidence that social enrichment has greater effects than handling on anxiety-like behaviors, neuroendocrine responses to stress and central BDNF levels | Q37695477 | ||
| Volume of the adrenal and pituitary glands in depression. | Q37774445 | ||
| Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease | Q37789909 | ||
| Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. | Q37930190 | ||
| Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. | Q38013453 | ||
| Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects | Q39119222 | ||
| Synaptic plasticity-regulated gene expression: a key event in the long-lasting changes of neuronal function | Q40118239 | ||
| Platelet monoamine oxidase activity in subjects tested for Huntington's disease gene mutation | Q40520687 | ||
| Environmental regulation of the development of glucocorticoid receptor systems in the rat forebrain. The role of serotonin | Q40572687 | ||
| Chronic glucocorticoid receptor activation impairs CREB transcriptional activity in clonal neurons | Q40650763 | ||
| Physiology of the neurotrophins | Q41132669 | ||
| The Neuropathology of CAG Repeat Diseases: Review and Update of Genetic and Molecular Features | Q41527060 | ||
| The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis | Q41527072 | ||
| Aripiprazole in the treatment of Huntington's disease: a case series | Q41529267 | ||
| Degenerative ataxias: genetics, pathogenesis and animal models | Q41573278 | ||
| Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? | Q41680087 | ||
| The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model | Q42055923 | ||
| Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males | Q42436584 | ||
| Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons | Q42466343 | ||
| Chronic high corticosterone reduces neurogenesis in the dentate gyrus of adult male and female rats. | Q42470493 | ||
| Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study | Q42492385 | ||
| Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. | Q42556936 | ||
| Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. | Q42609990 | ||
| Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice. | Q42671677 | ||
| Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes | Q42752136 | ||
| Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography. | Q42817778 | ||
| Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls | Q42936260 | ||
| Identification of a potential molecular link between the glucocorticoid and serotonergic signaling systems | Q43201583 | ||
| Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. | Q43227123 | ||
| Huntington's disease: current epidemiology and pharmacological management in UK primary care. | Q43453337 | ||
| Glucocorticoids and serotonin alter glucocorticoid receptor (GR) but not mineralocorticoid receptor (MR) mRNA levels in fetal mouse hippocampal neurons, in vitro | Q43558978 | ||
| Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives | Q43616412 | ||
| Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study | Q43620646 | ||
| Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. | Q43664408 | ||
| Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research | Q43789984 | ||
| Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. | Q44029969 | ||
| Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex | Q44048467 | ||
| Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease. | Q44116956 | ||
| SCA17, a novel polyglutamine disease caused by the expansion of polyglutamine tracts in TATA-binding protein | Q44139426 | ||
| Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. | Q44270223 | ||
| 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study | Q44359157 | ||
| Ziprasidone in Huntington's disease: the first case reports | Q44761187 | ||
| Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. | Q44804062 | ||
| A controlled psychiatric study of individuals at risk for Huntington's disease | Q45288655 | ||
| Psychopathology in Huntington's disease patients | Q45288763 | ||
| A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: looking for biomarkers | Q45290293 | ||
| A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. | Q45290515 | ||
| Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington's disease | Q45290562 | ||
| Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea | Q45291399 | ||
| Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease | Q45291543 | ||
| Health-related quality of life in Huntington's disease: Which factors matter most? | Q45292043 | ||
| Psychiatric symptoms and CAG expansion in Huntington's disease | Q45292106 | ||
| The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease | Q45292414 | ||
| L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease | Q45292472 | ||
| Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. | Q45292497 | ||
| Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin | Q45292690 | ||
| PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model | Q45292704 | ||
| Prevalence of major depression one year after predictive testing for Huntington's disease | Q45294623 | ||
| Validation of self-report depression rating scales in Huntington's disease | Q45295854 | ||
| 5-HT1B receptor binding in degenerative movement disorders | Q45295988 | ||
| Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk | Q45297711 | ||
| A retrospective study of the impact of lifestyle on age at onset of Huntington disease. | Q45298844 | ||
| Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. | Q45298962 | ||
| Depression and stages of Huntington's disease. | Q45299650 | ||
| Delaying the onset of Huntington's in mice | Q45300228 | ||
| Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury | Q45300518 | ||
| Altered emotional and motivational processing in the transgenic rat model for Huntington's disease. | Q45300705 | ||
| Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. | Q45301264 | ||
| Remotivation therapy and Huntington's disease | Q45303228 | ||
| Blood Monoamine Metabolism in Huntington's Disease | Q45303572 | ||
| Effects of depression on working memory in presymptomatic Huntington's disease | Q45303667 | ||
| Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic — Rigid form | Q45303946 | ||
| Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. | Q45304827 | ||
| Psychological impact of news of genetic risk for Huntington disease | Q45304894 | ||
| Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study | Q45305040 | ||
| Effect of CAG repeat length on psychiatric disorders in Huntington's disease | Q45305590 | ||
| Huntington's disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation | Q45305616 | ||
| Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. | Q45306546 | ||
| Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. | Q45307374 | ||
| Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats | Q45558675 | ||
| Density and distribution of white matter neurons in schizophrenia, bipolar disorder and major depressive disorder: no evidence for abnormalities of neuronal migration. | Q45774134 | ||
| Activity of the 5-HT1A receptor is involved in the alteration of glucocorticoid receptor in hippocampus and corticotropin-releasing factor in hypothalamus in SPS rats. | Q45939184 | ||
| PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. | Q46321226 | ||
| Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. | Q46531762 | ||
| Corticosteroid status influences the volume of the rat cingulate cortex - a magnetic resonance imaging study. | Q46578679 | ||
| Morphological correlates of corticosteroid-induced changes in prefrontal cortex-dependent behaviors. | Q46667868 | ||
| Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic, and biological correlations | Q46729008 | ||
| Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline | Q46817712 | ||
| Activation of the serotonin 5-HT2C receptor is involved in the enhanced anxiety in rats after single-prolonged stress | Q46859474 | ||
| Neuroplasticity and depression | Q46876771 | ||
| Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines | Q46878695 | ||
| Early social enrichment augments adult hippocampal BDNF levels and survival of BrdU-positive cells while increasing anxiety- and "depression"-like behavior | Q46943854 | ||
| Adrenal weight and morphology in victims of completed suicide | Q47369402 | ||
| Adrenal steroid regulation of neurotrophic factor expression in the rat hippocampus. | Q47914372 | ||
| Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus | Q48096317 | ||
| Enriched environment effects on behavior, memory and BDNF in low and high exploratory mice | Q48159550 | ||
| Relationship of brainstem raphe echogenicity and clinical findings in depressive states | Q48225983 | ||
| Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. | Q48294709 | ||
| Depression comorbidity in spinocerebellar ataxia | Q48310729 | ||
| Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. | Q48345283 | ||
| A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression | Q48381596 | ||
| Brain serotonin receptors in Huntington's disease. | Q48386883 | ||
| Glucocorticoid toxicity in the hippocampus. Temporal aspects of synergy with kainic acid | Q48399324 | ||
| Effects of long-term adrenalectomy on apoptosis and neuroprotection in the rat hippocampus | Q48492767 | ||
| 5-HT1A receptor agonist reverses adrenalectomy-induced loss of granule neuronal morphology in the rat dentate gyrus | Q48601196 | ||
| Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression | Q48662827 | ||
| Corticosterone regulates expression of BDNF and trkB but not NT-3 and trkC mRNA in the rat hippocampus | Q48706531 | ||
| Intact spatial learning and memory in transgenic mice with reduced BDNF. | Q48801407 | ||
| Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). | Q48824073 | ||
| Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs | Q48886408 | ||
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 81 | |
| P577 | publication date | 2013-07-09 | |
| P1433 | published in | Frontiers in Neurology | Q15817039 |
| P1476 | title | A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation | |
| P478 | volume | 4 |
| Q38244078 | Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? |
| Q47154575 | Disease-modifying effects of ganglioside GM1 in Huntington's disease models. |
| Q27346849 | Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease |
| Q28304384 | Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity |
| Q34407170 | Identifying novel interventional strategies for psychiatric disorders: integrating genomics, 'enviromics' and gene-environment interactions in valid preclinical models. |
| Q21131050 | Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms |
| Q28387085 | N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease |
| Q49339127 | Tandem repeats mediating genetic plasticity in health and disease |
| Q42861837 | The cell and molecular biology of neurodegenerative diseases: an overview |
Search more.